Market Research Reports and Industry Reports

Vistin Pharma AS (VISTIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies solid dosage forms and active pharmaceutical ingredients. The companys products include metformin, an API for the treatment of diabetes II; opioids, an analgesics and antitussive; and pholcodine, an antitussive. It provides contract manufacturing for granulate and solid dosage forms and offers customer service, logistics and technical services. Vistin offers plain generic and branded generic metformin tablets, and branded and patented combinations products. The company offers its services to international pharmaceutical companies. It operates through a network of distributors and agents across Europe, Asia, Africa and America. The companys manufacturing facilities are located in Sannidal and Kragero, Norway. Vistin is headquartered in Oslo, Norway.

Vistin Pharma AS (VISTIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vistin Pharma AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
Vistin Pharma Raises USD20 Million in Rights Offering of Shares 9
Asset Transactions 10
TPI Enterprises Acquires Opioids and CMO Business from Vistin Pharma 10
Acquisition 11
Geveran Trading Divests 5.17% Stake in Vistin Pharma 11
Vistin Pharma AS - Key Competitors 12
Vistin Pharma AS - Key Employees 13
Vistin Pharma AS - Locations And Subsidiaries 14
Head Office 14
Recent Developments 15
Financial Announcements 15
Oct 27, 2017: Vistin Pharma: Third quarter 2017 results - strong growth, capacity expansion on track 15
Apr 26, 2017: Vistin Pharma: First quarter 2017 results 16
Feb 28, 2017: Vistin Pharma: Fourth quarter and preliminary 2016 results 17
Oct 31, 2016: Vistin Pharma third quarter 2016: Investing in future growth 18
Aug 30, 2016: Vistin Pharma: Solid Second Quarter Driven by all-time High Metformin Revenue 19
Apr 28, 2016: Vistin Pharma : Strong First Quarter 2016 And Bright Outlook 20
Feb 23, 2016: Vistin Pharma: Solid Fourth Quarter Results and Positive Market Outlook 21
Other Significant Developments 22
Aug 31, 2017: Vistin Pharma Second quarter 2017 results - continuing strong demand for metformin 22
Dec 05, 2016: Vistin Pharma announces cost savings plan of NOK 20-30 million on an annualised basis 23
Nov 18, 2016: Vistin Pharmas metformin production temporarily halted due to an unscheduled maintenance stop 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List Of Tables

List of Tables
Vistin Pharma AS, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vistin Pharma AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Vistin Pharma Raises USD20 Million in Rights Offering of Shares 9
TPI Enterprises Acquires Opioids and CMO Business from Vistin Pharma 10
Geveran Trading Divests 5.17% Stake in Vistin Pharma 11
Vistin Pharma AS, Key Competitors 12
Vistin Pharma AS, Key Employees 13

Vistin Pharma AS (VISTIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies solid dosage forms and active pharmaceutical ingredients. The companys products include metformin,

USD 250View Report

Forward Pharma AS (FWP) - Financial and Strategic SWOT Analysis Review

Forward Pharma AS (Forward Pharma) is a biopharmaceutical company that develops immunomodulatory compound for the treatment of inflammatory and neurological indications. The company provides dimethyl fumarate and derivatives for the

USD 300View Report

Bionor Pharma ASA Strategic Analysis Review- Bionor Pharma ASA SWOT, Outlook, Operations and Financial Profile

Bionor Pharma ASA Company Profile provides strategic analysis of Bionor Pharma ASA Company in current market conditions. The companys business/ operational/growth strategies are analyzed in the unique research work. Growth

USD 200View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Dec 2017
No. of Pages :25
Country :Norway
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube